BroadOak Capital Partners focuses specifically on life science tools, diagnostics, and biopharma services companies, combining direct investing with an in-house FINRA/SIPC-member advisory bank so it can both fund companies and advise them on M&A and other strategic decisions, often using flexible debt structures backed by more than $200 million in permanent capital. It works closely with early-stage tools and diagnostics startups through programs like BioTools Innovator and the BroadOak BioTools Venture Fund, and it has advised companies such as ZoBio, KCAS, and Enzo Biochem on exits, buyouts, and other major ownership changes.